About
NorthLinks Bio is a clinical-stage biopharmaceutical company developing HEX17, an intranasal antiviral designed to provide broad-spectrum prophylactic protection against respiratory viruses by blocking viral entry at the point of infection.
Explore NorthLinks Bio's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.